Hospitex International, part of Aliko Scientific Group (Ticker: ALIKO), has announced the signing of a strategic distribution agreement with Naturneed to commercialize Urine24 in Italy – an innovative non-invasive diagnostic test designed for the early screening of bladder cancer. The agreement marks a key milestone in expanding access to advanced medical diagnostics and strengthening early cancer detection capabilities across the Italian healthcare market.
The partnership represents an important step in accelerating revenue growth for the Urine24 product line while expanding the reach of innovative oncology diagnostic technologies. Naturneed, a well-established Italian distributor specializing in the urology sector, will support the commercialization effort through its nationwide network of hospitals, urology clinics, and specialist physicians. With a dedicated commercial team of 25 key account managers, Naturneed will implement targeted clinical promotion strategies to increase adoption of the test among healthcare providers.
Under the terms of the agreement, minimum distribution targets have been established to maintain exclusivity. The agreement outlines 1,500 units for 2026 during the initial startup phase, increasing to 15,000 units in 2027 and 24,000 units in 2028. The transfer price for the product is set at €58 per unit, reinforcing the commercial scalability of the partnership.
Health Technology Insights: https://healthtechnologyinsights.com/medical-billing-automation-how-ai-is-ending-the-revenue-cycle-nightmare/
Urine24 represents a major advancement in non-invasive cancer diagnostics. The urine-based test identifies specific cellular and biomarker signals associated with bladder cancer, enabling earlier detection and supporting more timely clinical intervention. Bladder cancer is one of the most common malignancies affecting the urinary tract globally, with more than 570,000 new cases diagnosed annually. The growing global burden of this disease highlights the increasing need for innovative diagnostic technologies that can support early screening and improve patient outcomes.
By offering a simple urine-based approach, Urine24 complements existing urological diagnostic pathways. The test helps clinicians identify patients who may require further clinical investigation, enabling more proactive disease management while reducing reliance on more invasive diagnostic procedures.
The distribution agreement also reflects Aliko Scientific Group’s broader strategy to expand the commercialization of its oncology diagnostic technologies through specialized distribution partnerships and scalable healthcare sales infrastructures. In addition to commercial expansion, the company plans to support Urine24 adoption through scientific publications and clinical communications aimed at increasing awareness among urologists and healthcare professionals.
Francesco Trisolini, Group CEO of Aliko Scientific, highlighted the strategic significance of the agreement. “This collaboration is a significant step in Urine24’s commercial growth and shows that we can quickly establish organized distribution networks in crucial areas. Naturneed’s countrywide pharmacy availability and specialized urology network offer a solid platform for accelerating market penetration and supporting the Group’s oncology diagnostics revenue growth strategy.
Through this collaboration, Hospitex International and Aliko Scientific Group continue to strengthen their position as an integrated player in the oncology diagnostics sector while advancing the global commercialization of proprietary diagnostic technologies aimed at improving early cancer detection and patient care.
Health Technology Insights: https://healthtechnologyinsights.com/what-is-ais-role-in-radiology-exploring-its-impact-on-diagnostics/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
